SCN9A (Nav1.7) Expression Profile & Safety Assessment for Pain Drug Development

SCN9A (Nav1.7) Safety Profile Assessment

1. Tissue Expression Profile (Bgee Data) Highest Expression Tissues (Expression Score):

Tissue	Score	Category
Sural nerve	90.90	✅ Pain pathway (target)
Dorsal root ganglion	88.05	✅ Pain pathway (target)
Stromal cell of endometrium	83.65	⚠️ Reproductive
Trigeminal ganglion	80.31	✅ Pain pathway (target)
Male germ cells (testis)	78.17	⚠️ Reproductive
Calcaneal tendon	77.85	Connective tissue
Colonic epithelium	77.13	⚠️ GI tract
Tibial nerve	76.87	✅ Pain pathway
Liver	76.30	⚠️ Metabolic
Testis	73.52-76.06	⚠️ Reproductive
Hypothalamus	73.45	⚠️ CNS/Autonomic
Islets of Langerhans	72.88	⚠️ Pancreatic endocrine
Colon (various)	71-74	⚠️ GI tract
Spleen	71.79	Immune
Coronary arteries	58-60	⚠️ Cardiovascular

Key Finding: SCN9A is classified as ubiquitously expressed (187 tissues with detectable expression). While highest in sensory neurons (your target), significant expression exists in multiple off-target systems.

---

2. Non-Pain Tissues with Safety Concerns

System	Tissues	Potential Concern
Reproductive	Testis, endometrial stroma, germ cells	Fertility effects
Gastrointestinal	Colonic epithelium, rectum, small intestine	GI motility, secretion
Cardiovascular	Coronary arteries, heart regions	Cardiac conduction
Endocrine	Pancreatic islets, pituitary, hypothalamus	Glucose homeostasis, autonomic function
Hepatic	Liver	Metabolic effects
Autonomic CNS	Hypothalamus, substantia nigra	Autonomic regulation

---

3. Human Phenotypes from SCN9A Dysfunction Loss-of-function mutations (relevant to your inhibitor):

Phenotype	HPO ID	Clinical Relevance
Pain insensitivity	HP:0007021	Desired effect
Anosmia (loss of smell)	HP:0000458	Well-documented
Hyposmia	HP:0004409	Olfactory deficit
Anhidrosis	HP:0000970	Sweat gland dysfunction
Hypohidrosis	HP:0000966	Reduced sweating
Xerostomia (dry mouth)	HP:0000217	Salivary gland effect
Lacrimation abnormality	HP:0000632	Tear production
Constipation	HP:0002019	GI dysmotility
Diarrhea	HP:0002014	GI effects
Bradycardia	HP:0001662	Cardiac effect
Tachycardia	HP:0001649	Cardiac effect
Hypothermia	HP:0002045	Thermoregulation

Associated Disease Syndromes:

Condition	Mutation Type	Key Features
Congenital insensitivity to pain (OMIM:243000)	Loss-of-function	Complete pain insensitivity, anosmia
Primary erythermalgia (MONDO:0007571)	Gain-of-function	Burning pain, flushing
Paroxysmal extreme pain disorder (MONDO:0008179)	Gain-of-function	Rectal/ocular/submandibular pain

---

4. Safety Implications Summary High-Priority Monitoring Areas for Clinical Trials:

1. Olfactory function - Anosmia is consistently observed in SCN9A loss-of-function; include smell testing
2. Autonomic function - Sweating, tear/saliva production, thermoregulation
3. GI motility - Constipation/diarrhea monitoring
4. Cardiac - ECG monitoring for conduction effects
5. Reproductive - Consider fertility assessments given testicular expression
6. Glucose homeostasis - Monitor given pancreatic islet expression Favorable Safety Signals:

• Individuals with congenital SCN9A loss-of-function are otherwise healthy and have normal lifespan

• No major organ dysfunction reported beyond sensory/autonomic phenotypes Risk Mitigation Considerations:

• Peripheral-restricted inhibitors may reduce CNS/autonomic effects

• Dose-response characterization for olfactory function

• Short-acting formulations may reduce cumulative autonomic effects This analysis should help inform your clinical trial design. The anosmia risk is the most well-established off-target effect - consider including validated smell tests (e.g., UPSIT) in your safety monitoring protocol.